Literature DB >> 21826648

Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells.

Yu-Hua Hsieh1, M Margaret Juliana, Kang-Jey Ho, Hui-Chien Kuo, Henri van der Heyde, Craig Elmets, Pi-Ling Chang.   

Abstract

The matricellular protein osteopontin (OPN), expressed in various cancer types and elevated in the blood of cancer patients, is thought to have different functions when derived from host versus cancer cells. To assess the effect of host-derived OPN on growth of cancers of epithelial origin, we established a line of cutaneous squamous cell carcinoma (SCC) cells, named ONSC, which lacks the OPN gene and develops SCC in syngeneic wild-type (WT) and OPN-null mice. At 8 and/or 10 week after subcutaneous injection of ONSC cells in mice, however, there was a lower tumor incidence in WT mice, suggesting that host-derived OPN is associated with suppression of early growth of extrinsic cancer cells. Histological, immunohistochemical, biochemical and hematological analyses were performed on the tumor microenvironment and blood from tumor-bearing mice during the first week after implantation. Host-derived OPN suppression of extrinsic ONSC cell progression is likely mediated through elicitation of an early innate inflammatory response, through its function as a chemoattractant and/or by enhancing survival of inflammatory cells. Further, consistent with a previous report, the serum levels of host-derived OPN, which are elevated during the early phase of tumor growth in mice implanted with ONSC, appear to reflect an anti-tumor progression effect.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826648      PMCID: PMC3635472          DOI: 10.1002/ijc.26359

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  47 in total

1.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

2.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

3.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

Review 4.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

5.  Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin.

Authors:  Yu-Hua Hsieh; M Margaret Juliana; Patricia H Hicks; Gong Feng; Craig Elmets; Lucy Liaw; Pi-Ling Chang
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

6.  Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity.

Authors:  R E Devoll; W Li; K V Woods; G J Pinero; W T Butler; M C Farach-Carson; R P Happonen
Journal:  J Oral Pathol Med       Date:  1999-03       Impact factor: 4.253

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Osteopontin functions as an opsonin and facilitates phagocytosis by macrophages of hydroxyapatite-coated microspheres: implications for bone wound healing.

Authors:  Claudio E Pedraza; Liliya G Nikolcheva; Mari T Kaartinen; Jake E Barralet; Marc D McKee
Journal:  Bone       Date:  2008-07-04       Impact factor: 4.398

9.  Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice.

Authors:  Veerle P Persy; Anja Verhulst; Dirk K Ysebaert; Kathleen E De Greef; Marc E De Broe
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

Review 10.  Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology.

Authors:  Franziska Buback; Andreas C Renkl; Guido Schulz; Johannes M Weiss
Journal:  Exp Dermatol       Date:  2009-06-23       Impact factor: 3.960

View more
  7 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development.

Authors:  Pi-Ling Chang; Yu-Hua Hsieh; Chao-Cheng Wang; M Margaret Juliana; Yuko Tsuruta; Laura Timares; Craig Elmets; Kang-Jey Ho
Journal:  J Dermatol Sci       Date:  2014-05-21       Impact factor: 4.563

3.  Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.

Authors:  Frank Szulzewsky; Nina Schwendinger; Dilansu Güneykaya; Patrick J Cimino; Dolores Hambardzumyan; Michael Synowitz; Eric C Holland; Helmut Kettenmann
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

4.  HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells.

Authors:  N E James; E Cantillo; M T Oliver; R B Rowswell-Turner; J R Ribeiro; K-K Kim; C O Chichester; P A DiSilvestro; R G Moore; R K Singh; N Yano; T C Zhao
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

5.  Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels.

Authors:  S R Rittling; P L Wejse; K Yagiz; G A Warot; T Hui
Journal:  Br J Cancer       Date:  2014-01-28       Impact factor: 7.640

Review 6.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

7.  TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation.

Authors:  Yongchang Chen; Lu Liu; Longzheng Xia; Nayiyuan Wu; Ying Wang; He Li; Xue Chen; Xiaoye Zhang; Zhaoyi Liu; Miaochen Zhu; Qianjin Liao; Jing Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.